BioIVT expands into new therapy areas with Fidelis acquisition

BioIVT has acquired Fidelis Research, an 85-site clinical biospecimen collection network in Southeastern Europe. 

Fidelis Research also possesses cell isolation capabilities and provides custom contract research services for pharmaceutical companies and clinical research organisations (CROs). 

“This transaction increases BioIVT’s global operations by adding new clinical collection sites, which are predominantly hospital based, focused on oncology, heme-oncology, and autoimmune cases,” said Dr Richard Haigh, BioIVT Chief Executive Officer (CEO).

Within the past year, BioIVT has undertaken a programme to annotate thousands of biospecimens with next-generation sequencing data (NGS), creating the largest biorepository of biospecimens with mutation or genotype data. 

Through the acquisition of Fidelis, BioIVT will be able to expand into multiple therapeutic areas, most notably in oncology. 

Shannon Richey, Vice President at BioIVT, added: “I am especially excited to add biospecimens collected through the Fidelis network to our NGS annotation programme.”

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free